Barry Ticho Sells 4,504 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Key Points

• Insider Barry Ticho sold 4,504 shares of Stoke Therapeutics at an average price of $12.82, reducing his holdings by 21.17% to a total of 16,775 shares valued at approximately $215,055.50.
• Stoke Therapeutics stock has seen a 1.3% decline recently, currently trading at $12.97, following a release of mixed analyst ratings and target prices ranging from $22.00 to $35.00.
• Several institutional investors have increased their stake in Stoke Therapeutics, including RTW Investments LP and Baker BROS. Advisors LP, which saw significant purchases in the past quarter.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 4,504 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the completion of the transaction, the insider directly owned 16,775 shares of the company's stock, valued at $215,055.50. The trade was a 21.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Barry Ticho also recently made the following trade(s):

• On Tuesday, June 3rd, Barry Ticho sold 6,471 shares of Stoke Therapeutics stock. The shares were sold at an average price of $10.03, for a total value of $64,904.13.
• On Monday, June 2nd, Barry Ticho sold 1,745 shares of Stoke Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $17,450.00.

Stoke Therapeutics Trading Down 0.5%

STOK stock traded down $0.07 during midday trading on Thursday, hitting $13.10. 201,128 shares of the company's stock were exchanged, compared to its average volume of 778,772. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $16.15. The stock has a market capitalization of $715.22 million, a price-to-earnings ratio of 16.63 and a beta of 1.15. The firm has a 50 day moving average price of $11.91 and a 200-day moving average price of $9.93.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics in the fourth quarter worth about $63,000. AlphaQuest LLC bought a new position in Stoke Therapeutics during the 1st quarter valued at approximately $72,000. US Bancorp DE increased its holdings in Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after buying an additional 11,108 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Stoke Therapeutics in the first quarter worth approximately $92,000.

Wall Street Analysts Forecast Growth

STOK has been the topic of several research reports. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price target on the stock. HC Wainwright reduced their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $25.80.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.